An Australasian and French Phase III, Multicentre, Randomised Trial Comparing Lenalidomide Consolidation versus No Consolidation in Patients With Chronic Lymphocytic Leukaemia and Residual Disease Following Induction Chemotherapy (CLL6)

Full description

This dataset contains individual participant data (IPD) from the CLL6 study, a phase III randomised trial evaluating lenalidomide consolidation versus no consolidation in patients with chronic lymphocytic leukaemia (CLL) with residual disease following induction chemotherapy. The dataset includes patient-level demographic and clinical information such as age, sex, disease characteristics, prognostic markers, and baseline laboratory values. Treatment data include consolidation therapy allocation, dosing, and duration. Outcome data include response assessments, minimal residual disease status, progression-free survival, overall survival, and adverse events. The study population comprises approximately 192 adult patients with CLL and residual disease following induction therapy. Data are collected at predefined timepoints including baseline, post-induction, during consolidation (where applicable), and during scheduled follow-up for disease assessment and survival outcomes. Participants were recruited at sites in, Australia wide). The study commenced in 2011 and conducted the last patient last visit in 2018. This dataset is suitable for secondary analyses including evaluation of consolidation strategies, disease response, long-term outcomes, and optimisation of treatment approaches in CLL.

Notes

HeSANDA 1.0.0